Published in Drug Law Weekly, February 8th, 2005
Earlier, in July 2004, Ranbaxy had said that the company would make its first ARV filing with the U.S. FDA under the PEPFAR, by the end of 2004. Ranbaxy has met this expectation and has filed two additional ARVs with the U.S. FDA after its first ARV filing in October 2004.
Speaking on the occasion, Dr. Brian W. Tempest, CEO and managing director of Ranbaxy, said, "We are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.